Lactate/GPR81 recruits regulatory T cells by modulating CX3CL1 to promote immune resistance in a highly glycolytic gastric cancer

IF 7.2 2区医学

Oncoimmunology Pub Date : 2024-02-26 DOI:10.1080/2162402x.2024.2320951

Jin Su, Xinyuan Mao, Lingzhi Wang, Zhian Chen, Weisheng Wang, Cuiyin Zhao, Guoxin Li, Weihong Guo, Yanfeng Hu

引用次数: 0

Abstract

Lactate plays an important role in shaping immune tolerance in tumor microenvironment (TME) and correlates with poor prognosis in various solid tumors. Overcoming the immune resistance in an acidic...

查看原文本刊更多论文

乳酸/GPR81 通过调节 CX3CL1 招募调节性 T 细胞，促进高糖酵解胃癌的免疫抵抗力

乳酸盐在形成肿瘤微环境（TME）免疫耐受方面起着重要作用，并与各种实体瘤的不良预后相关。克服酸性环境中的免疫耐受...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.